Jefferies Assumes Immunomedics (IMMU) at Buy
Get Alerts IMMU Hot Sheet
Rating Summary:
13 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 14 | New: 22
Join SI Premium – FREE
Jefferies assumes coverage on Immunomedics (NASDAQ: IMMU) with a Buy rating and a price target of $5.50 (from $5.00).
Analyst Matthew Andrews commented, "Assuming coverage with a Buy Rating and $5.50 price target. IMMU-132 has generated promising results in Triple Negative breast cancer and we believe clin/reg/CMC progress in 2016 sets the stage for a deal in the coming months ahead of Ph. III start by late 2016/early 2017. Based on '132's TNBC profile and FDA precedent, we assign a 55% probability of Accelerated Approval (AA) based on Ph. II data in 2018."
For an analyst ratings summary and ratings history on Immunomedics click here. For more ratings news on Immunomedics click here.
Shares of Immunomedics closed at $2.50 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- China Resources Beer Holdings Co Ltd. (291:HK) (CRHKY) PT Raised to HK$44.67 at Jefferies
- Matador Resources Company (MTDR) PT Raised to $76 at Mizuho
- CIBC Starts Wesdome Gold Mines Ltd. (WDO:CN) (WDOFF) at Outperformer
Create E-mail Alert Related Categories
Analyst Comments, Hot New Coverage, New CoverageRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!